Skip to main content
. Author manuscript; available in PMC: 2021 May 28.
Published in final edited form as: Adv Drug Deliv Rev. 2020 May 28;154-155:245–273. doi: 10.1016/j.addr.2020.05.006

Figure 1:

Figure 1:

Overview of mechanisms for monoconstituents of CHMs on tumor cells and the TME (Abbreviation: MRP, multidrug resistance-associated protein; GS-conjugates, glutathione conjugates; P-gp, P-glycoprotein; BCRP, breast cancer resistance-relative protein; TGF-β, transforming growth factor-β; IL-10, interleukin-10; IFN-γ, interferon gamma; TNF-α, tumor necrosis factor-alpha).